0000000000613623

AUTHOR

Alessandro Russo

showing 30 related works from this author

Ceftazidime-avibactam use for klebsiella pneumoniae carbapenemase-producing k. pneumoniae infections: A retrospective observational multicenter study

2021

Abstract Background A growing body of observational evidence supports the value of ceftazidime-avibactam (CAZ-AVI) in managing infections caused by carbapenem-resistant Enterobacteriaceae. Methods We retrospectively analyzed observational data on use and outcomes of CAZ-AVI therapy for infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae (KPC-Kp) strains. Multivariate regression analysis was used to identify variables independently associated with 30-day mortality. Results were adjusted for propensity score for receipt of CAZ-AVI combination regimens versus CAZ-AVI monotherapy. Results The cohort comprised 577 adults with bloodstream infections (n = 391) or nonba…

Microbiology (medical)Adultmedicine.medical_specialtyAzabicyclo CompoundcarbapenemasesBacterial ProteinMicrobial Sensitivity TestsNeutropeniaCeftazidimebeta-Lactamasesbeta-LactamaseCarbapenemasecarbapenemaseBacterial ProteinsRetrospective StudieLower respiratory tract infectionInternal medicineDrug CombinationAnti-Bacterial AgentmedicineHumansKPC-producing Klebsiella pneumoniaeRetrospective StudiesSeptic shockbusiness.industryCeftazidime-avibactamMicrobial Sensitivity Testceftazidime-avibactamMortality rateCarbapenemases; Ceftazidime-avibactam; KPC-producing Klebsiella pneumoniae; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Drug Combinations; Humans; Microbial Sensitivity Tests; Retrospective Studies; beta-Lactamases; Klebsiella Infections; Klebsiella pneumoniaeKPC-producing Klebsiella pneumoniae; carbapenemases; ceftazidime-avibactammedicine.diseaseCeftazidime/avibactamSettore MED/17KPC-producing Klebsiella pneumoniae; carbapenemases; ceftazidime-avibactam; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Drug Combinations; Humans; Microbial Sensitivity Tests; Retrospective Studies; beta-Lactamases; Klebsiella Infections; Klebsiella pneumoniaeAnti-Bacterial AgentsKlebsiella InfectionsDrug CombinationsKlebsiella pneumoniaeInfectious DiseasesCohortPropensity score matchingObservational studybusinessAzabicyclo Compoundsmedicine.drugHumanKlebsiella Infection
researchProduct

Central nervous system involvement in ALK-rearranged NSCLC : promising strategies to overcome crizotinib resistance

2016

ABSTRACT: Introduction: ALK rearranged Non Small Cell Lung Cancers (NSCLCs) represent a distinct subgroup of patients with peculiar clinic-pathological features. These patients exhibit dramatic responses when treated with the ALK tyrosine kinase inhibitor Crizotinib, albeit Central Nervous System (CNS) activity is much less impressive than that observed against extracranial lesions. CNS involvement has become increasingly observed in these patients, given their prolonged survival. Several novel generation ALK inhibitors have been developing to increase CNS penetration and to provide more complete ALK inhibition. Areas covered: The CNS activity of Crizotinib and novel generation ALK inhibito…

0301 basic medicineLung NeoplasmsSettore MED/06 - Oncologia MedicaPyridinesPyridineDrug ResistanceNSCLCTyrosine-kinase inhibitorALK translocations Brain metastases central nervous system metastases leptomeningeal metastases NSCLC Animals Antineoplastic Agents Brain Neoplasms Carcinoma Non-Small-Cell Lung Drug Design Drug Resistance Neoplasm Gene Rearrangement Humans Lung Neoplasms Protein Kinase Inhibitors Pyrazoles Pyridines Receptor Protein-Tyrosine Kinases Oncology Pharmacology (medical)Cns penetrationAntineoplastic Agent0302 clinical medicinecentral nervous system metastasesCarcinoma Non-Small-Cell Lunghemic and lymphatic diseasesMedicinePharmacology (medical)Anaplastic Lymphoma Kinaseleptomeningeal metastaseNon-Small-Cell LungGene RearrangementBrain NeoplasmsReceptor Protein-Tyrosine Kinasemedicine.anatomical_structureOncology030220 oncology & carcinogenesisNon small cellHumanmedicine.drugBrain metastasemedicine.drug_classCentral nervous systemProtein Kinase InhibitorCNS InvolvementAntineoplastic AgentsALK translocationBrain Neoplasm03 medical and health sciencesCrizotinibAnimalsHumansCns activityCrizotinib resistanceProtein Kinase Inhibitorsleptomeningeal metastasescentral nervous system metastaseCrizotinibAnimalbusiness.industryCarcinomaReceptor Protein-Tyrosine KinasesBrain metastasesLung Neoplasm030104 developmental biologyALK translocationsDrug Resistance NeoplasmDrug DesignPyrazoleImmunologyCancer researchNeoplasmPyrazolesHuman medicinebusinessExpert review of anticancer therapy
researchProduct

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

2020

In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular pre…

0301 basic medicineOncologyProto-Oncogene Proteins B-rafmedicine.medical_specialtyPredictive molecular pathologyLung NeoplasmsGene mutationBRAF03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungMedicineHumansNon-Small-Cell LungVemurafenibLung cancerneoplasmsMelanomaTrametinibCobimetinibbusiness.industryBRAF; Lung cancer; Melanoma; Precision medicine; Predictive molecular pathology; Biomarkers; Humans; Mutation; Proto-Oncogene Proteins B-raf; Carcinoma Non-Small-Cell Lung; Lung Neoplasms; MelanomaCarcinomaPrecision medicineDabrafenibHematologyBiomarkerPrecision medicinemedicine.diseaseBRAF; Lung cancer; Melanoma; Precision medicine; Predictive molecular pathologyLung Neoplasm030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisMutationPersonalized medicineLung cancerbusinessBiomarkersmedicine.drugHuman
researchProduct

Healthcare-Associated Pneumonia and Multidrug Resistant Bacteria: Do We Have a Convincing Answer?

2014

Methicillin-Resistant Staphylococcus aureusMicrobiology (medical)medicine.medical_specialtyBacteriabusiness.industryMedicine (all)Drug ResistanceBacterialPneumonia Ventilator-AssociatedBacteria; Enterobacteriaceae; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia Ventilator-Associated; Pseudomonas aeruginosa; Drug Resistance Bacterial; Infectious Diseases; Microbiology (medical); Medicine (all)Pneumoniamedicine.diseasePneumoniaVentilator-AssociatedMultidrug resistant bacteriaInfectious DiseasesHealthcare associatedEnterobacteriaceaeDrug Resistance BacterialPseudomonas aeruginosamedicineBacteria; Enterobacteriaceae; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia; Ventilator-Associated; Pseudomonas aeruginosa; Drug Resistance; Bacterial; Infectious Diseases; Microbiology (medical); Medicine (all)HumansIntensive care medicinebusiness
researchProduct

P1.06-046 Can We Better Manage Advanced NSCLC in the Elderly with the New Therapeutic Agents? Preliminary Analysis of a Real-Life Multicenter Study

2017

Pulmonary and Respiratory Medicinemedicine.medical_specialtyOncologyMulticenter studybusiness.industrymedicineIntensive care medicinebusinessPreliminary analysisJournal of Thoracic Oncology
researchProduct

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with …

2016

// Giuseppe Bronte 1, * , Tindara Franchina 2, * , Massimiliano Alu 3, * , Giovanni Sortino 1 , Claudia Celesia 1 , Francesco Passiglia 1 , Giuseppina Savio 3 , Agata Laudani 3 , Alessandro Russo 2 , Antonio Picone 2 , Sergio Rizzo 1 , Michele De Tursi 4 , Elisabetta Gambale 4 , Viviana Bazan 1 , Clara Natoli 4 , Livio Blasi 3 , Vincenzo Adamo 2 , Antonio Russo 1 1 Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy 2 Medical Oncology Unit-AOOR Papardo-Piemonte, Messina and Department of Human Pathology, University of Messina, Messina, Italy 3 Medical Oncology Unit, A.R.N.A.S. Civico, Palermo, Italy 4 Department of Medical, Oral and Biotechnological …

Male0301 basic medicineOncologymedicine.medical_specialtyLung Neoplasmsmedicine.drug_classEGFRTyrosine kinase inhibitorKaplan-Meier EstimateTyrosine-kinase inhibitorErlotinib Hydrochloride03 medical and health sciences0302 clinical medicineGefitinibCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansChemotherapyErlotinib HydrochlorideLung cancerProtein Kinase InhibitorsChemotherapy EGFR Non-small-cell lung cancer Tyrosine kinase inhibitor OncologyAgedRetrospective StudiesAged 80 and overPerformance statusbusiness.industryChemotherapy; EGFR; Non-small-cell lung cancer; Tyrosine kinase inhibitor; OncologyGefitinibRetrospective cohort studyMiddle Agedmedicine.diseaserespiratory tract diseasesSurgeryErbB ReceptorsClinical trialTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisMutationQuinazolinesFemaleErlotinibbusinessNon-small-cell lung cancerResearch Papermedicine.drug
researchProduct

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

2020

Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a signifi…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentClinical BiochemistryKaplan-Meier EstimateDisease-Free SurvivalDrug Administration ScheduleNO03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungDrug DiscoverymedicineMalignant pleural effusionHumansimmunotherapy; malignant pleural effusion; nivolumab; non-small-cell lung cancerIn patientmalignant pleural effusionLung cancerImmune Checkpoint InhibitorsRetrospective StudiesPharmacologynivolumabbusiness.industryBrain NeoplasmsLiver NeoplasmsImmunotherapymedicine.diseasePrognosisPleural Effusion Malignantrespiratory tract diseases030104 developmental biologyTreatment Outcomenon-small-cell lung cancer030220 oncology & carcinogenesisFemalesense organsNon small cellimmunotherapyNivolumabbusiness
researchProduct

Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary resu…

2006

BACKGROUND: Mammaglobin is expressed mainly in mammary tissue, overexpressed in breast cancer (BC) and rarely in other tissue. The aim of this study was to assess the sensitivity and specificity of transcript MGB1 detection and to evaluate the role of MGB1 as potential clinical marker for the detection of disseminated cancer cells in the blood of BC patients. PATIENTS AND METHODS: A consecutive series of 23 BC tissues, 36 peripheral blood BC samples and 35 healthy peripheral blood samples was prospectively recruited to investigate MGB1 expression by means of a quantitative Real Time RT-PCR assay. RESULTS: MGB1 overexpression in tissue samples of BC patients is significantly associated only …

OncologyAdultmedicine.medical_specialtyPathologySettore MED/06 - Oncologia MedicaMrna expressionClinical markerBreast NeoplasmsSensitivity and SpecificityMammaglobinBreast cancerInternal medicinemedicineBiomarkers TumorHumansUteroglobinProspective StudiesRNA MessengerProspective cohort studyAgedAged 80 and overbiologybusiness.industryReverse Transcriptase Polymerase Chain ReactionMammaglobin AMammary tissuemammaglobyn brest cancerHematologyMiddle Agedmedicine.diseaseNeoplastic Cells CirculatingPeripheral bloodNeoplasm ProteinsOncologybiology.proteinFemalebusinessDisseminated cancer
researchProduct

The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lun…

2015

Oncologymedicine.medical_specialtybusiness.industrymedicine.drug_classWild typeHematologymedicine.diseaseTyrosine-kinase inhibitorOncologyThird lineInternal medicinemedicineRetrospective analysisMutational statusNon small cellbusinessLung cancerAnnals of Oncology
researchProduct

The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrosp…

2015

e19030 Background: Second-line treatment for advanced non-small-cell lung cancer (aNSCLC) patients includes monotherapy with a third generation cytotoxic drug (CT) or with the tyrosine kinase inhib...

Cancer Researchmedicine.drug_classbusiness.industryWild typePharmacologymedicine.diseaseTyrosine-kinase inhibitorThird generationSecond lineOncologymedicineCancer researchRetrospective analysisNon small cellLung cancerbusinessTyrosine kinaseJournal of Clinical Oncology
researchProduct

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC…

2020

Introduction: Immune checkpoint inhibitors have provided substantial benefit in non-small cell lung cancer (NSCLC) with unprecedented results in terms of survival. However, the identification of reliable predictive biomarkers to these agents is lacking and multiple clinicopathological factors have been evaluated. The aim of this study was to analyze the potential role of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) levels in patients with pretreated NSCLC receiving nivolumab. Methods: This was a retrospective multicenter study involving 14 Italian centers, evaluating the role of some laboratory results in patients with NSCLC treat…

OncologyMale030213 general clinical medicineLung NeoplasmsNeutrophilsLymphocytenon-small cell lung cancer (NSCLC)DiseaseNSCLCchemistry.chemical_compoundLeukocyte Count0302 clinical medicineAntineoplastic Agents ImmunologicalCarcinoma Non-Small-Cell LungPD-180 and overLeukocytesPharmacology (medical)LymphocytesNon-Small-Cell LungAged 80 and overbiologyGeneral MedicineMiddle AgedPrognosisImmunologicalmedicine.anatomical_structureNivolumab030220 oncology & carcinogenesisLDH; Nivolumab; NLR; NSCLC; PD-1; PD-L1; PLR; Prognosis; Adult; Aged; Aged 80 and over; Antineoplastic Agents Immunological; Biomarkers; Carcinoma Non-Small-Cell Lung; Female; Humans; Leukocyte Count; Leukocytes; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Nivolumab; Prognosis; Retrospective StudiesFemaleNivolumabAdultPD-L1medicine.medical_specialtyLDHAntineoplastic AgentsPLRNONLR03 medical and health sciencesPD-L1Lactate dehydrogenaseInternal medicinemedicineHumansNeutrophil to lymphocyte ratioAgedRetrospective Studiesbusiness.industryCarcinomamedicine.diseaseRheumatologychemistrybiology.proteinLDH; Nivolumab; NLR; NSCLC; PD-1; PD-L1; PLR; PrognosisbusinessBiomarkers
researchProduct

Additional file 4: of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Supplementary Results section. (PDF 123 kb)

3. Good health
researchProduct

Poor timing and failure of source control are risk factors for mortality in critically ill patients with secondary peritonitis

2022

PURPOSE: To describe data on epidemiology, microbiology, clinical characteristics and outcome of adult patients admitted in the intensive care unit (ICU) with secondary peritonitis, with special emphasis on antimicrobial therapy and source control. METHODS: Post hoc analysis of a multicenter observational study (Abdominal Sepsis Study, AbSeS) including 2621 adult ICU patients with intra-abdominal infection in 306 ICUs from 42 countries. Time-till-source control intervention was calculated as from time of diagnosis and classified into 'emergency' ( 6 h). Relationships were assessed by logistic regression analysis and reported as odds ratios (OR) and 95% confidence interval (CI). RESULTS: The…

AdultSecondary peritonitiCritical IllnessPeritonitisCritical Care and Intensive Care MedicineAnti-Bacterial AgentsAntimicrobial therapyIntensive Care UnitsSecondary peritonitisIntra-abdominal infectionAnti-Infective AgentsRisk FactorsSource controlSepsisMedicine and Health SciencesHumansIntraabdominal InfectionsMortalityRetrospective StudiesAntimicrobial therapy; Intra-abdominal infection; Mortality; Secondary peritonitis; Source controlIntensive Care Medicine
researchProduct

Additional file 5: of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Figure S1-S6 with corresponding figure legends. (PDF 511 kb)

3. Good health
researchProduct

Additional file 5: of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Figure S1-S6 with corresponding figure legends. (PDF 511 kb)

3. Good health
researchProduct

Additional file 4: of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Supplementary Results section. (PDF 123 kb)

3. Good health
researchProduct

Antimicrobial Lessons From a Large Observational Cohort on Intra-abdominal Infections in Intensive Care Units

2021

Severe intra-abdominal infection commonly requires intensive care. Mortality is high and is mainly determined by disease-specific characteristics, i.e. setting of infection onset, anatomical barrier disruption, and severity of disease expression. Recent observations revealed that antimicrobial resistance appears equally common in community-acquired and late-onset hospital-acquired infection. This challenges basic principles in anti-infective therapy guidelines, including the paradigm that pathogens involved in community-acquired infection are covered by standard empiric antimicrobial regimens, and second, the concept of nosocomial acquisition as the main driver for resistance involvement. I…

Drug Resistancemedicine.disease_causeSeverity of Illness Indexlaw.invention0302 clinical medicineENTEROBACTERIACEAElawDrug Resistance Multiple BacterialMedicine and Health SciencesPharmacology (medical)Cross InfectionbiologyBacterialAntimicrobialIntensive care unitAnti-Bacterial AgentsCommunity-Acquired InfectionsEuropeIntensive Care UnitsAnti-Bacterial Agents; Community-Acquired Infections; Critical Illness; Cross Infection; Europe; Humans; Intensive Care Units; Intraabdominal Infections; Microbial Sensitivity Tests; Peritonitis; Sepsis; Severity of Illness Index; Drug Resistance Multiple BacterialESCHERICHIA-COLI030220 oncology & carcinogenesisKLEBSIELLA-PNEUMONIAEBLOOD-STREAM INFECTIONSPYELONEPHRITISMultiplemedicine.medical_specialtyCritical IllnessMicrobial Sensitivity TestsPeritonitisEnterococcus faecalisNO03 medical and health sciencesIntra‑abdominal InfectionsAntibiotic resistanceFOODSepsisIntensive careInternal medicinemedicineHumansFLUOROQUINOLONE RESISTANCEPseudomonas aeruginosabusiness.industrySeptic shockMORTALITYbiology.organism_classificationmedicine.diseaseRISK-FACTORSIntraabdominal Infectionsbusiness030217 neurology & neurosurgeryEnterococcus faecium
researchProduct

Additional file 2: Table S2. of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Description, functional classification, abundance profile and mass spectrometry identification parameters of differentially represented Microbispora ATCC-PTA-5024 proteins identified from global proteome analysis at D substages. (XLS 107 kb)

researchProduct

Additional file 6: Table S5. of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Description, abundance profile and mass spectrometry identification parameters of differentially represented spots containing multiple protein components. (XLS 45 kb)

researchProduct

Additional file 3: Table S3. of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Description, functional classification, abundance profile and mass spectrometry identification parameters of differentially represented Microbispora ATCC-PTA-5024 proteins identified from membrane proteome analysis at A substages. (XLSX 37 kb)

researchProduct

Additional file 2: Table S2. of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Description, functional classification, abundance profile and mass spectrometry identification parameters of differentially represented Microbispora ATCC-PTA-5024 proteins identified from global proteome analysis at D substages. (XLS 107 kb)

researchProduct

Additional file 6: Table S5. of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Description, abundance profile and mass spectrometry identification parameters of differentially represented spots containing multiple protein components. (XLS 45 kb)

researchProduct

Additional file 7: Table S4. of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Description, functional classification, abundance profile and mass spectrometry identification parameters of differentially represented proteins due to NAI-107 exposure in Microbispora ATCC-PTA-5024 RP0 strain. (XLSX 32 kb)

researchProduct

Additional file 1: Table S1. of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Description, functional classification, abundance profile and mass spectrometry identification parameters of differentially represented Microbispora ATCC-PTA-5024 proteins identified from global proteome analysis at A substages. (XLSX 48 kb)

researchProduct

Additional file 8: Table S6. of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Numbers of KEGG orthology groups participating in molecular and metabolic processes as inferred from genome and proteome analyses, respectively. (XLS 24 kb)

funginatural sciences
researchProduct

Additional file 3: Table S3. of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Description, functional classification, abundance profile and mass spectrometry identification parameters of differentially represented Microbispora ATCC-PTA-5024 proteins identified from membrane proteome analysis at A substages. (XLSX 37 kb)

researchProduct

Additional file 7: Table S4. of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Description, functional classification, abundance profile and mass spectrometry identification parameters of differentially represented proteins due to NAI-107 exposure in Microbispora ATCC-PTA-5024 RP0 strain. (XLSX 32 kb)

researchProduct

Additional file 8: Table S6. of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Numbers of KEGG orthology groups participating in molecular and metabolic processes as inferred from genome and proteome analyses, respectively. (XLS 24 kb)

funginatural sciences
researchProduct

Neutrophil-To-Lymphocyte Ratio (NLR) Platelet-To-Lymphocyte Ratio (PLR), and Outcomes With Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC)…

2020

Provide enhanced digital features for this article This Figshare page contains a Summary Slide. If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact adisrapidplus@springer.com. The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure informati…

researchProduct

Additional file 1: Table S1. of Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024

2016

Description, functional classification, abundance profile and mass spectrometry identification parameters of differentially represented Microbispora ATCC-PTA-5024 proteins identified from global proteome analysis at A substages. (XLSX 48 kb)

researchProduct